Skye Bioscience, Inc.
SKYE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $166 | $63 | $113 |
| - Cash | $18 | $24 | $46 | $68 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $142 | $17 | $45 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$13 | -$17 | -$11 | -$10 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$18 | -$11 | -$10 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.32 | -0.44 | -0.28 | -0.24 |
| % Growth | 27.3% | -57.1% | -16.7% | – |
| Operating Cash Flow | -$13 | -$11 | -$9,185 | -$8 |
| Capital Expenditures | -$0 | -$0 | -$6 | -$0 |
| Free Cash Flow | -$13 | -$11 | -$9,192 | -$8 |